Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:


	Weighted-Average Life (Years)	Original Cost		Accumulated Amortization		Net Book Value
Definite-lived intangible assets
Distribution right	20	$	59,076	$	(8,589)	$	50,487
Capitalized software	2	7,314		(7,176)		138
Intangible assets, net		66,390		(15,765)		50,625
Indefinite-lived intangible asset
Goodwill	*	21,208		—		21,208
Total as of December 31, 2021		$	87,598	$	(15,765)	$	71,833


	Weighted-Average Life (Years)	Original Cost		Accumulated Amortization		Net Book Value
Definite-lived intangible assets
Distribution right	20	$	59,076	$	(5,650)	$	53,426
Capitalized software	2	6,681		(4,810)		1,871
Intangible assets, net		65,757		(10,460)		55,297
Indefinite-lived intangible asset
Goodwill	*	21,208		—		21,208
Total as of December 31, 2020		$	86,965	$	(10,460)	$	76,505

* Intangible assets with indefinite lives have an indeterminable average life.

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2021 that are subject to amortization:


Fiscal year
2022	3,016
2023	3,034
2024	2,955
2025	2,955
2026	2,955
Thereafter	35,710
	$	50,625

Distribution right represents the license and associated distribution right to develop Jeuveau®, the initial term of which expires in September 2023 and is automatically extended for unlimited additional three-year terms provided that the Company meets certain performance requirements. Additionally, upon FDA approval of Jeuveau® on February 1, 2019, the IPR&D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of 20 years. The Company paid Daewoong a $2,000 milestone payment, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. In connection with EU approval of Jeuveau®, the Company paid a $1,000 milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which increased the cost basis of the distribution right. Under the Daewoong Arrangement (as defined in Note 11.), there is no additional cash consideration due to Daewoong. See Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement for additional information.

For the years ended December 31, 2021 and 2020, the Company capitalized $633 and $2,266, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method. For the years ended December 31, 2021 and 2020, total intangible assets amortization expense of $5,305 and $3,635, respectively, was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss.